HEAL Group takes majority stake in German cannabis firm Grünhorn
What's the deal? The HEAL GroupDealroom has a profile for this one. Try Dealroom → has acquired a majority stake in the Grünhorn GruppeDealroom has a profile for this one. Try Dealroom →, one of Germany's leading suppliers of medical cannabis. The deal closed in July 2026; terms were not disclosed. Pava PartnersDealroom has a profile for this one. Try Dealroom → advised Grünhorn's shareholders exclusively.
What each side brings: Grünhorn combines a mail-order pharmacy, pharmaceutical wholesale, fulfilment and logistics, and telemedical patient care in one integrated model. HEAL is a privately held, international healthcare and health tech group operating in Canada, the US, the UK, and Germany.
Why now? Germany's medical cannabis market has grown quickly since regulatory reforms. In that setting, scale, procurement, supply reliability, and compliance carry more weight — areas where Grünhorn already has established infrastructure.
What's the endgame? HEAL wants to build on Grünhorn's market position and drive further growth. Grünhorn gains access to a larger procurement and partner network, plus room to expand its product portfolio and platform.
HEAL is already active in the German market through Khiron Life SciencesDealroom has a profile for this one. Try Dealroom →, its international medical cannabis unit. It says it brings existing German market knowledge, experience scaling healthcare businesses, and an international network.
The signal: The deal points to consolidation in Germany's medical cannabis sector, where integrated players linking patients, doctors, and pharmacies are gaining ground as the market matures.
Read more: majunke.com
Image credit: Generated with Gemini
